Cadila Pharmaceuticals
Research
Biologics Development

At Dholka, near Ahmedabad, our Biotechnology R&D and manufacturing facilities serve as the heart of our biologics work. Supported by a DSIR-approved research centre, our teams focus on process development and advanced research, building precise, reliable biologic solutions with care, consistency, and scientific integrity.

We bring together comprehensive capabilities across research and development, GMP manufacturing, and analytics to serve a bigger purpose, advancing healthcare that truly makes a difference. Through these strengths, we strive to provide innovative, high-quality solutions to global healthcare challenges, with care, consistency, and scientific rigour at the core.

Backed by deep technical expertise, we continue to foster innovation while remaining dedicated to bringing accessible, affordable products to market, so that better treatment reaches more people, wherever they are.

Built on strong science and future-facing technology, our research centre is designed to respond swiftly to emerging health challenges while staying rooted in patient need.

  • Collaborating with international and national research institutions like ICGEB, CSIR, NII, DST, and IMTECH

  • Launched India’s first VLP-based influenza vaccines for H1N1-Swine Flu and Seasonal Flu using Sf9/BV technology

  • Commercialised innovative three-dose rabies vaccine for post-exposure prophylaxis, which is also made using the Sf9/BV platform

  • Indian licensure of the first recombinant Rabies G protein nanoparticle-based vaccine for post-exposure prophylaxis, which is also made using the Sf9/BV platform

  • Research program focusing on developing a nanoparticle-based vaccine for the varicella zoster virus. GMP manufacturing facilities are equipped to produce recombinant vaccines for all clinical trial phases and commercialisation

  • CPLB’s production process of highly purified recombinant vaccines  to produce full-length or near full-length viral proteins

  • The technology has been proven to respond rapidly to emerging threats to human health

  • The GMP manufacturing processes are based on single-use technology

  • Commercial Biologicals like Erythropoietin, Filgrastim, Streptokinase, and immunomodulatory agents

  • GMP facilities and expertise on Mammalian, microbial, insect, and viral culturing techniques

  • Integrated Pre-clinical (GLP) and US FDA-approved clinical facilities on site

Across molecular biology and manufacturing scale-up, our biotech capabilities are made to support every stage of biological product development with care, depth, and scientific accuracy.

Molecular Biology

  • Clone Development

  • Molecular assays

  • Clone stability studies

Upstream Processing and Capabilities

  • Mammalian cell culture system for recombinant proteins

  • Virus culture, bacterial fermentation for natural and recombinant proteins

  • Insect cell baculovirus expression system for recombinant proteins

  • Microbial culture

  • Perfusion and continuous culture

  • Batch and fed batch culture

  • Clarification

  • Series of SS fermenters and single-use bioreactors, process development, scale-up, and manufacturing 

Downstream Processing and Capabilities

  • Chromatography techniques

  • Separation technologies
    - Filtration
    - Centrifugation

  • Solvent Extraction

  • Purification of natural and recombinant proteins

  • Development of a robust purification process

  • Technology transfer to manufacturing and scale-up

  • High-throughput DSP systems

Analytical Development

  • Physico-chemical assay

  • Immunoanalysis

  • Biochemical assay

  • Potency assay

  • Animal model

  • Challenge assay

  • Cell-based assays

  • Glycan profiling

Our value proposition is rooted in decades of scientific pursuit, technical depth and an unwavering commitment to human health.

<p><strong><meta charset="utf-8"></strong><span style="white-space:pre-wrap;"><strong>Track Record</strong></span></p>

Track Record

Developed and commercialised a wide range of biologicals (including biosimilars) and vaccines, strengthening trust through proven science and real-world impact.

<p><strong><meta charset="utf-8"></strong><span style="white-space:pre-wrap;"><strong>Technology</strong></span></p>

Technology

Expertise across multiple platform technologies, including microbial and cell culture, powering innovation at every stage of biological development.

<p><strong><meta charset="utf-8"></strong><span style="white-space:pre-wrap;"><strong>Successful CDMO</strong></span></p>

Successful CDMO

A trusted CDMO partner in Botulinum Toxin and Antiplatelet–Anticoagulant domains, supporting global partners with reliable, scalable solutions.

<p><strong><meta charset="utf-8"></strong><span style="white-space:pre-wrap;"><strong>Policy Systems and Support</strong></span></p>

Policy Systems and Support

Robust quality systems backed by integrated support divisions, ensuring consistency, compliance, and confidence across operations.

downWhiteCurveArrow
footer-logo

Contact Us

contact-icon
+91 22 66220000
Contact Us
FacebookInstagramLinkedinXYoutube
Privacy PolicyADR ReportingDrug Counterfeiting

Corporate Identification No : U24231GJ1991PLC015132

©2026 Cadila Pharmaceuticals. All rights reserved